【CSCO 2022 Prospect】The domestic drug serplulimab brings new hope to esophageal cancer patients

The incidence of esophageal cancer in China is relatively high
.
According to data from the World Health Organization, in 2020, there were 324,000 new cases of esophageal cancer and 301,000 deaths in China, accounting for 53.
70% and 55.
35%
of the global incidence and death of esophageal cancer, respectively.
The early symptoms of esophageal cancer are not obvious, most patients are often in the middle and advanced stages when they are diagnosed, resulting in a generally low survival rate of patients, the current clinical use of systemic therapy (chemotherapy or targeted therapy) for advanced patients, but the treatment effect is limited, the recurrence rate and metastasis rate are high, and new drugs and treatment options
are urgently needed in clinical practice.

In recent years, tumor immunotherapy has become one of the research hotspots at home and abroad, and a number of studies have shown that anti-PD-1 monoclonal antibody combined with chemotherapy can bring survival benefits to patients with esophageal cancer, and immune checkpoint inhibitors combined with chemotherapy have become the first-line treatment standard
for esophageal cancer in China.

Serplulimab is a domestic PD-1 immunotherapy drug, which was approved for marketing in China in March 2022 for the treatment of unresectable, metastatic highly microsatellite unstable (MSI-H) solid tumors
.
ASTRUM-007 is a randomized, double-blind, multicenter, phase III clinical study with Professor Huang Jing of the Cancer Hospital of the Chinese Academy of Medical Sciences as the principal investigator to compare the efficacy and safety
of serplulimab or placebo in combination with chemotherapy in patients with locally advanced/metastatic esophageal squamous cell carcinoma.
In May 2022, the results of the interim analysis of the study showed that serplulimab plus chemotherapy showed significant improvements in progression-free survival (PFS) and overall survival (OS) compared with placebo plus chemotherapy, meeting the preset efficacy criteria, and having a good
safety profile.

On November 5, 2022, Professor Huang Jing will attend the CSCO Annual Meeting with the topic "First-line serplulimab versus placebo in combination with chemotherapy in PD-L1-positive esophageal squamous cell carcinoma (ASTRUM-007): a randomized.
" , double-blind, multicenter phase 3 study", brings us the latest progress of ASTRUM-007 research, and expects that the domestic drug serplulimab can bring new prospects
for the treatment of esophageal cancer patients and the research and development of local innovative drugs.

Resources:

https://mp.
weixin.
qq.
com/s/2GP7O9ahJ-_qk6w4KoFKFg

https://mp.
weixin.
qq.
com/s/z0HQFUppUbM7-3bkC2vGLA

https://mp.
weixin.
qq.
com/s/zvNqNfKtEY9el0XBkS6YPA

https://mp.
weixin.
qq.
com/s/s57lTHCSsoULsh9o9phdlw